logo-loader
Physiomics Plc

Renewal of key Merck contract caps off “strong” first half for Physiomics

“Building on the momentum generated by existing and new contracts as well as success in attracting grant funding in the calendar year 2018, we are looking forward to what the directors believe will be a strong second half, underpinned by contracts already secured”

tumour scan
Physiomics’ technology helps to improve R&D success rates

The renewal of a key contract with German pharma giant Merck Serono capped off a “strong” first half for Physiomics Plc (LON:PYC).

Merck has long been a fan of the AIM company’s Virtual Tumour programme – a piece of software that can predict the effect of different combinations of drugs on cancers.

The £435,000 deal agreed in December was an extension of a long-standing relationship between the two firms.

READ: Physiomics striking up new relationships in world of oncology

They struck a similar deal at the end of 2017, something which was reflected in Physiomics’ first-half results this time around.

It helped income soar to £372,000 (H1 17: £142,000) in the six months ended 31 December, while it also contributed to a near-50% drop in operating losses to £113,000 (H1 17: £220,000).

At the end of the period, the company had £552,000 of cash in the bank, compared with £166,000 at the end of 2017.

As well as the Merck deal, Physiomics bagged other contracts during the first half, including from a new European biotech client, while a £48,000 grant from Innovate UK – the UK government’s innovation agency – also helped boost the performance in the first half.

Bosses are attending some big industry conferences over the next few months which they hope will drum up more interest in its software and lead to new client wins further down the line.

 “Building on the momentum generated by existing and new contracts as well as success in attracting grant funding in the calendar year 2018, we are looking forward to what the directors believe will be a strong second half, underpinned by contracts already secured,” read Thursday’s results statement.

Physiomics shares fell 4.3% to 3.35p on Thursday morning.

Quick facts: Physiomics Plc

Price: £0.03

Market: AIM
Market Cap: £2.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Physiomics Plc named herein, including the promotion by the Company of Physiomics Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Firestone Diamonds unearths largest stone yet

Top stories from the Proactive Investors UK newsroom. Firestone Diamonds (LON:DFI) has unearthed its largest fancy yellow diamond yet from the Liqhobong Mine in Lesotho. Paul Bosma, chief executive, said the intense yellow 54 carat stone will go on sale in September. Physiomics...

on 8/7/19

2 min read